Certain Sleep-Disordered Breathing Treatment Systems and Components Thereof; Notice of Institution of Investigation; Institution of Investigation Pursuant to 19 U.S.C. 1337, 52563-52564 [2013-20638]
Download as PDF
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 164 / Friday, August 23, 2013 / Notices
consultation process of the National
Historic Preservation Act (16 U.S.C.
470f), as provided for in 36 CFR
800.2(d)(3).
Pursuant to the regulations
implementing the procedural provisions
of NEPA (42 U.S.C. 4321 et seq.), BOEM
will hold public scoping meetings in
Louisiana, Mississippi, and Alabama on
the CPA Supplemental EIS. The purpose
of these meetings is to solicit comments
on the scope of the CPA Supplemental
EIS. BOEM’s scoping meetings will be
held at the following places and times:
• Gulfport, Mississippi: Monday,
September 9, 2013, Courtyard by
Marriott Beachfront MS Hotel, 1600 East
Beach Boulevard, Gulfport, Mississippi
39501; one meeting beginning at 6:30
p.m. CDT;
• Mobile, Alabama: Tuesday,
September 10, 2013, Hilton Garden Inn
Mobile West, 828 West I–65 Service
Road South, Mobile, Alabama 36609;
one meeting beginning at 6:30 p.m.
CDT; and
• New Orleans, Louisiana: Thursday,
September 12, 2013, Bureau of Ocean
Energy Management, Gulf of Mexico
OCS Region, 1201 Elmwood Park
Boulevard, New Orleans, Louisiana
70123; one meeting beginning at 1:00
p.m. CDT.
Cooperating Agency: BOEM invites
other Federal, State, Tribal, and local
governments to consider becoming
cooperating agencies in the preparation
of the CPA Supplemental EIS. We invite
qualified government entities to inquire
about cooperating agency status for the
CPA Supplemental EIS. Following the
guidelines from the Council on
Environmental Quality (CEQ), qualified
agencies and governments are those
with ‘‘jurisdiction by law or special
expertise.’’ Potential cooperating
agencies should consider their authority
and capacity to assume the
responsibilities of a cooperating agency,
and remember that an agency’s role in
the environmental analysis neither
enlarges nor diminishes the final
decisionmaking authority of any other
agency involved in the NEPA process.
Upon request, BOEM will provide
potential cooperating agencies with a
written summary of ground rules for
cooperating agencies, including time
schedules and critical action dates,
milestones, responsibilities, scope and
detail of cooperating agencies’
contributions, and availability of
predecisional information. BOEM
anticipates this summary will form the
basis for a Memorandum of Agreement
between BOEM and any cooperating
agency. Agencies should also consider
the ‘‘Factors for Determining
Cooperating Agency Status’’ in
VerDate Mar<15>2010
17:28 Aug 22, 2013
Jkt 229001
Attachment 1 to CEQ’s January 30, 2002,
Memorandum for the Heads of Federal
Agencies: Cooperating Agencies in
Implementing the Procedural
Requirements of the National
Environmental Policy Act. These
documents are available at the following
locations on the Internet: https://ceq.hss.
doe.gov/nepa/regs/cooperating/
cooperatingagenciesmemorandum.html;
and https://ceq.hss.doe.gov/nepa/regs/
cooperating/cooperatingagencymemo
factors.html.
BOEM, as the lead agency, will not
provide financial assistance to
cooperating agencies. Even if an
organization is not a cooperating
agency, opportunities will exist to
provide information and comments to
BOEM during the normal public input
stages of the NEPA/EIS process. For
further information about cooperating
agencies, please contact Mr. Gary D.
Goeke at (504) 736–3233.
Comments: All interested parties,
including Federal, State, Tribal, and
local governments, and other interested
parties, may submit written comments
on the scope of the CPA Supplemental
EIS, significant issues that should be
addressed, alternatives that should be
considered, potential mitigation
measures, and the types of oil and gas
activities of interest in the proposed
CPA lease sale area.
Written scoping comments may be
submitted in one of the following ways:
1. In an envelope labeled ‘‘Scoping
Comments for the CPA Supplemental
EIS’’ and mailed (or hand delivered) to
Mr. Gary D. Goeke, Chief,
Environmental Assessment Section,
Office of Environment (GM 623E),
Bureau of Ocean Energy Management,
Gulf of Mexico OCS Region, 1201
Elmwood Park Boulevard, New Orleans,
Louisiana 70123–2394;
2. Through the regulations.gov web
portal: Navigate to https://
www.regulations.gov and search for ‘‘Oil
and Gas Lease Sales: Gulf of Mexico,
Outer Continental Shelf; Central
Planning Area Lease Sales 235, 241, and
247’’ (Note: It is important to include
the quotation marks in your search
terms.) Click on the ‘‘Comment Now!’’
button to the right of the document link.
Enter your information and comment,
then click ‘‘Submit’’; or
3. BOEM’s email address: cpa235@
boem.gov.
Petitions, although accepted, do not
generally provide useful information to
assist in the development of
alternatives, resources and issues to be
analyzed, or impacting factors. BOEM
does not consider anonymous
comments; please include your name
and address as part of your submittal.
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
52563
BOEM makes all comments, including
the names and addresses of
respondents, available for public review
during regular business hours.
Individual respondents may request that
BOEM withhold their names and/or
addresses from the public record;
however, BOEM cannot guarantee that
we will be able to do so. If you wish
your name and/or address to be
withheld, you must state your
preference prominently at the beginning
of your comment. All submissions from
organizations or businesses and from
individuals identifying themselves as
representatives or officials of
organizations or businesses will be
made available for public inspection in
their entirety.
DATES: Comments should be submitted
by September 23, 2013 to the address
specified above.
FOR FURTHER INFORMATION CONTACT: For
information on the CPA Supplemental
EIS, the submission of comments, or
BOEM’s policies associated with this
notice, please contact Mr. Gary D.
Goeke, Chief, Environmental
Assessment Section, Office of
Environment (GM 623E), Bureau of
Ocean Energy Management, Gulf of
Mexico OCS Region, 1201 Elmwood
Park Boulevard, New Orleans, LA
70123–2394, telephone (504) 736–3233.
Authority: This NOI is published pursuant
to the regulations (40 CFR 1501.17)
implementing the provisions of NEPA.
Dated:August 16, 2013.
Tommy P. Beaudreau,
Director, Bureau of Ocean Energy
Management.
[FR Doc. 2013–20649 Filed 8–22–13; 8:45 am]
BILLING CODE 4310–MR–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–890]
Certain Sleep-Disordered Breathing
Treatment Systems and Components
Thereof; Notice of Institution of
Investigation; Institution of
Investigation Pursuant to 19 U.S.C.
1337
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on July
19, 2013, under section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, on behalf of ResMed Corporation
of San Diego, California; ResMed
SUMMARY:
E:\FR\FM\23AUN1.SGM
23AUN1
52564
Federal Register / Vol. 78, No. 164 / Friday, August 23, 2013 / Notices
Incorporated of San Diego, California;
and ResMed Limited of Australia. The
complaint alleges violations of section
337 based upon the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain sleepdisordered breathing treatment systems
and components thereof by reason of
infringement of certain claims of U.S.
Patent No. 7,997,267 (‘‘the ’267 patent’’),
U.S. Patent No. 7,614,398 (‘‘the ’398
patent’’), U.S. Patent No. 7,938,116 (‘‘the
’116 patent’’), U.S. Patent No. 7,341,060
(‘‘the ’060 patent’’), U.S. Patent No.
8,312,883 (‘‘the ’883 patent’’), U.S.
Patent No. 7,926,487 (‘‘the ’487 patent’’),
U.S. Patent No. 7,178,527 (‘‘the ’527
patent’’), and U.S. Patent No. 7,950,392
(‘‘the ’392 patent’’). The complaint
further alleges that an industry in the
United States exists as required by
subsection (a)(2) of section 337.
The complainants request that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and cease and
desist orders.
The complaint, except for
any confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street SW., Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at (202) 205–
2000. General information concerning
the Commission may also be obtained
by accessing its internet server at
https://www.usitc.gov. The public record
for this investigation may be viewed on
the Commission’s electronic docket
(EDIS) at https://edis.usitc.gov.
ADDRESSES:
The
Office of Unfair Import Investigations,
U.S. International Trade Commission,
telephone (202) 205–2560.
Authority: The authority for
institution of this investigation is
contained in section 337 of the Tariff
Act of 1930, as amended, and in section
210.10 of the Commission’s Rules of
Practice and Procedure, 19 CFR 210.10
(2013).
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
August 16, 2013, ordered that—
tkelley on DSK3SPTVN1PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
VerDate Mar<15>2010
17:28 Aug 22, 2013
Jkt 229001
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(B) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain sleep-disordered
breathing treatment systems and
components thereof that infringe one or
more of claims 32–37, 53, 79, 80, and 88
of the ’267 patent; claims 1–7 of the ’398
patent; claim 1 of the ’116 patent; claims
30, 37, and 38 of the ’060 patent; claims
1, 3, 5, 11, 28, 30, 31, and 56 of the ’883
patent; claims 1, 3, 6, 7, 9, 29, 32, 35,
40, 42, 45, 50, 51, 56, 59, 89, 92, 94, and
96 of the ’527 patent; claims 19–24, 26,
29–36, and 39–41 of the ’392 patent; and
claims 13, 15, 16, 26–28, 51, 52, and 55
of the ’487 patent; and whether an
industry in the United States exists as
required by subsection (a)(2) of section
337;
(2) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainants are: ResMed
Corporation, 9001 Spectrum Center
Drive, San Diego, CA 92123.
ResMed Incorporated, 9001 Spectrum
Center Drive, San Diego, CA 92123.
ResMed Limited, 1 Elizabeth
Macarthur Drive, Bella Vista NSW 2153,
Australia.
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
BMC Medical Co., Ltd., 5/F Main
Building, No. 19 Gucheng Street West,
Shijingshan, Beijing 100043, China.
3B Medical, Inc., 21301 US Highway
27, Lake Wales, FL 33589.
3B Products, L.L.C., 21301 US
Highway 27, Lake Wales, FL 33589.
(c) The Office of Unfair Import
Investigations, U.S. International Trade
Commission, 500 E Street SW., Suite
401, Washington, DC 20436; and
(3) For the investigation so instituted,
the Chief Administrative Law Judge,
U.S. International Trade Commission,
shall designate the presiding
Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(e) and 210.13(a), such
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
the respondent.
Issued: August 19, 2013.
By order of the Commission.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013–20638 Filed 8–22–13; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF LABOR
Office of the Secretary
Agency Information Collection
Activities; Submission for OMB
Review; Comment Request; Survey of
Occupational Injuries and Illnesses
ACTION:
Notice.
The Department of Labor
(DOL) is submitting the Bureau of Labor
Statistics (BLS) sponsored information
collection request (ICR) revision titled,
‘‘Survey of Occupational Injuries and
Illnesses,’’ to the Office of Management
and Budget (OMB) for review and
approval for use in accordance with the
Paperwork Reduction Act (PRA) of 1995
(44 U.S.C. 3501 et seq.).
DATES: Submit comments on or before
September 23, 2013.
ADDRESSES: A copy of this ICR with
applicable supporting documentation;
including a description of the likely
respondents, proposed frequency of
response, and estimated total burden
may be obtained free of charge from the
RegInfo.gov Web site at https://
www.reginfo.gov/public/do/
PRAViewICR?ref_nbr=201305-1220-002
(this link will only become active on the
day following publication of this notice)
or by contacting Michel Smyth by
telephone at 202–693–4129 (this is not
a toll-free number) or sending an email
to DOL_PRA_PUBLIC@dol.gov.
SUMMARY:
E:\FR\FM\23AUN1.SGM
23AUN1
Agencies
[Federal Register Volume 78, Number 164 (Friday, August 23, 2013)]
[Notices]
[Pages 52563-52564]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-20638]
=======================================================================
-----------------------------------------------------------------------
INTERNATIONAL TRADE COMMISSION
[Investigation No. 337-TA-890]
Certain Sleep-Disordered Breathing Treatment Systems and
Components Thereof; Notice of Institution of Investigation; Institution
of Investigation Pursuant to 19 U.S.C. 1337
AGENCY: U.S. International Trade Commission.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that a complaint was filed with the
U.S. International Trade Commission on July 19, 2013, under section 337
of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, on behalf of
ResMed Corporation of San Diego, California; ResMed
[[Page 52564]]
Incorporated of San Diego, California; and ResMed Limited of Australia.
The complaint alleges violations of section 337 based upon the
importation into the United States, the sale for importation, and the
sale within the United States after importation of certain sleep-
disordered breathing treatment systems and components thereof by reason
of infringement of certain claims of U.S. Patent No. 7,997,267 (``the
'267 patent''), U.S. Patent No. 7,614,398 (``the '398 patent''), U.S.
Patent No. 7,938,116 (``the '116 patent''), U.S. Patent No. 7,341,060
(``the '060 patent''), U.S. Patent No. 8,312,883 (``the '883 patent''),
U.S. Patent No. 7,926,487 (``the '487 patent''), U.S. Patent No.
7,178,527 (``the '527 patent''), and U.S. Patent No. 7,950,392 (``the
'392 patent''). The complaint further alleges that an industry in the
United States exists as required by subsection (a)(2) of section 337.
The complainants request that the Commission institute an
investigation and, after the investigation, issue a limited exclusion
order and cease and desist orders.
ADDRESSES: The complaint, except for any confidential information
contained therein, is available for inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S.
International Trade Commission, 500 E Street SW., Room 112, Washington,
DC 20436, telephone (202) 205-2000. Hearing impaired individuals are
advised that information on this matter can be obtained by contacting
the Commission's TDD terminal on (202) 205-1810. Persons with mobility
impairments who will need special assistance in gaining access to the
Commission should contact the Office of the Secretary at (202) 205-
2000. General information concerning the Commission may also be
obtained by accessing its internet server at https://www.usitc.gov. The
public record for this investigation may be viewed on the Commission's
electronic docket (EDIS) at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT: The Office of Unfair Import
Investigations, U.S. International Trade Commission, telephone (202)
205-2560.
Authority: The authority for institution of this investigation is
contained in section 337 of the Tariff Act of 1930, as amended, and in
section 210.10 of the Commission's Rules of Practice and Procedure, 19
CFR 210.10 (2013).
Scope of Investigation: Having considered the complaint, the U.S.
International Trade Commission, on August 16, 2013, ordered that--
(1) Pursuant to subsection (b) of section 337 of the Tariff Act of
1930, as amended, an investigation be instituted to determine whether
there is a violation of subsection (a)(1)(B) of section 337 in the
importation into the United States, the sale for importation, or the
sale within the United States after importation of certain sleep-
disordered breathing treatment systems and components thereof that
infringe one or more of claims 32-37, 53, 79, 80, and 88 of the '267
patent; claims 1-7 of the '398 patent; claim 1 of the '116 patent;
claims 30, 37, and 38 of the '060 patent; claims 1, 3, 5, 11, 28, 30,
31, and 56 of the '883 patent; claims 1, 3, 6, 7, 9, 29, 32, 35, 40,
42, 45, 50, 51, 56, 59, 89, 92, 94, and 96 of the '527 patent; claims
19-24, 26, 29-36, and 39-41 of the '392 patent; and claims 13, 15, 16,
26-28, 51, 52, and 55 of the '487 patent; and whether an industry in
the United States exists as required by subsection (a)(2) of section
337;
(2) For the purpose of the investigation so instituted, the
following are hereby named as parties upon which this notice of
investigation shall be served:
(a) The complainants are: ResMed Corporation, 9001 Spectrum Center
Drive, San Diego, CA 92123.
ResMed Incorporated, 9001 Spectrum Center Drive, San Diego, CA
92123.
ResMed Limited, 1 Elizabeth Macarthur Drive, Bella Vista NSW 2153,
Australia.
(b) The respondents are the following entities alleged to be in
violation of section 337, and are the parties upon which the complaint
is to be served:
BMC Medical Co., Ltd., 5/F Main Building, No. 19 Gucheng Street
West, Shijingshan, Beijing 100043, China.
3B Medical, Inc., 21301 US Highway 27, Lake Wales, FL 33589.
3B Products, L.L.C., 21301 US Highway 27, Lake Wales, FL 33589.
(c) The Office of Unfair Import Investigations, U.S. International
Trade Commission, 500 E Street SW., Suite 401, Washington, DC 20436;
and
(3) For the investigation so instituted, the Chief Administrative
Law Judge, U.S. International Trade Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the notice of investigation must be
submitted by the named respondents in accordance with section 210.13 of
the Commission's Rules of Practice and Procedure, 19 CFR 210.13.
Pursuant to 19 CFR 201.16(e) and 210.13(a), such responses will be
considered by the Commission if received not later than 20 days after
the date of service by the Commission of the complaint and the notice
of investigation. Extensions of time for submitting responses to the
complaint and the notice of investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely response to each
allegation in the complaint and in this notice may be deemed to
constitute a waiver of the right to appear and contest the allegations
of the complaint and this notice, and to authorize the administrative
law judge and the Commission, without further notice to the respondent,
to find the facts to be as alleged in the complaint and this notice and
to enter an initial determination and a final determination containing
such findings, and may result in the issuance of an exclusion order or
a cease and desist order or both directed against the respondent.
Issued: August 19, 2013.
By order of the Commission.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013-20638 Filed 8-22-13; 8:45 am]
BILLING CODE 7020-02-P